Gardner Lewis Asset Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Gardner Lewis Asset Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-370,123	Closed	-$255K	–	92
2020 Q4	$255K	Sell	370,123 -175,000	-32%	-$373K	0.06%	66
2020 Q3	$1.23M	Buy	545,123 +50,000	+10%	+$143K	0.22%	63
2020 Q2	$1.77M	Hold	495,123	–	–	0.33%	53
2020 Q1	$1.88M	Sell	495,123 -30,088	-6%	-$99.1K	0.31%	55
2019 Q4	$1.58M	Buy	+525,211	New	+$1.37M	0.22%	69

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Gardner Lewis Asset Management's BMY.RT Position: Q1 2021 in Review

Gardner Lewis Asset Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 370,123 shares — an estimated $255K sold.

Gardner Lewis Asset Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.88M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Gardner Lewis Asset Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Gardner Lewis Asset Management sold 370,123 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $255K.
Gardner Lewis Asset Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Gardner Lewis Asset Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.88M in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Gardner Lewis Asset Management's 13F filing for Q1 2021, filed 14 May 2021.